Strategic alliance announced between Recipharm and Exela
October 1, 2024Research and Development Corporate, Exela, Recipharm, US
Recipharm and Exela have announced that they have entered into an exclusive strategic alliance. The alliance between the two contract …
Santhera Pharmaceuticals announces LIONHEART study results for corticosteroid vamorolone
October 1, 2024Research and Development Cardiology, Duchenne Muscular Dystrophy, Immunology, Santhera Pharmaceuticals, clinical studies
Santhera Pharma has announced the results of its LIONHEART study, which evaluated vamorolone – a corticosteroid – and confirmed its …
Prilenia appoints new management staff to advance company’s development and commercialisation plans
September 30, 2024Corporate, prilenia
Prilenia, a clinical stage biotech focusing on neurodegenerative and neurodevelopmental disorders, has announced the appointment of two new senior staff …
Vertex Highlights First Oral Presentation of Phase 3 Clinical Dataof the Vanzacaftor Triple Combination and New Data on Long-Term Impact of TRIKAFTA at the North American CysticFibrosis Conference
September 30, 2024Vertex Pharma
Phase 3 data on investigational vanzacaftor triple combination demonstrates noninferiorityto TRIKAFTA® in ppFEV1 and further improvement of CFTR functionas measured …
Eli Lilly announces two senior hires in Public Affairs and Communications team
September 27, 2024Corporate, Eli Lilly
Pharmaceutical company Eli Lilly has announced the appointment of two senior positions in its Public Affairs and Communications team. James …
Laurence Reid and Brad Crutchfield appointed to Broken Strings’ board of directors
September 25, 2024Broken String Biosciences, Corporate
Cambridge, UK-based genomics company Broken String Biosciences has announced the appointment of Laurence Reid PhD as chairman, and Brad Crutchfield …
Third application for Orion’s prostate cancer drug submitted by partner Bayer
September 23, 2024Bayer, Cancer, Oncology, orion, prostate cancer
Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application of its prostate cancer drug, …
Expanded possibilities for laboratory digitalization and connectivity: labforward merges with LabTwin
September 19, 2024Business Services, Research and Development AI, Corporate, LabTwin, laboratory
The two Berlin-based companies labforward and LabTwin, a subsidiary of the life science group Sartorius, are merging in order to …
Steriline’s founder “passes torch” to children with CEO and CSO appointments
September 19, 2024Corporate, Steriline
Aseptic packaging company Steriline’s founder Gerardo Fumagalli has “passed the torch” to his children Illaria Fumagalli and Federico Fumagalli, who …
Butterfly Network Expands its Next-Generation Butterfly iQ3™ to Europe
September 11, 2024Butterfly Network, medical imaging
Butterfly iQ3 is built on the next-generation Ultrasound-on-Chip™ technology featuring unparalleled image quality, new 3D imaging capabilities, and a smaller, …
Chiesi Global Rare Diseases Launches New Research Grant Initiative to Support Research Excellence in Lysosomal Storage Disorders
September 9, 2024Research and Development Rare Diseases
9 September 2024, –London, UK –Applications for the independently assessed, expert-led Research Grant Initiative, Find For Rare, are open from …
Amferia closes €1,2 million investment to combat resistant bacterial infections
September 3, 2024Research and Development Amferia, Chalmers Ventures, Dressings, hosiery & appliances, Hospital Management, Immunology, antimicrobial, investment, peptides
Swedish medtech company Amferia announces the successful completion of its latest investment round, boosting its mission to combat wound infections. …
The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis
August 29, 2024Research and Development AbbVie, Crohns, Gastrointestinal tract, Immunology, NICE, approval, ulcerative colitis
The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England or Wales with moderately or …
Leadership Appointments at RQM+
August 28, 2024Research and Development AI and ML, Corporate, RQM+, appointment
Ronnie Mahofski and Kevin Rowland both become Executive Vice President and General Manager On August 27, MedTech service provider RQM+ announced …
European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
August 27, 2024Research and Development J&J, Oncology, chemotherapy, non-small cell lung cancer
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined …
New gastric & gastro-oesophageal junction cancer treatment VYLOY™ ▼ (zolbetuximab): the first claudin 18.2 biomarker targeted therapy licensed in Great Britain
August 16, 2024GEJ cancers, Gastrointestinal tract, MHRA, Oncology, gastric cancer
Claudin18.2 is an innovative drug-target which is not currently used for any other authorised treatment. There is a large unmet …
First oral treatment for hormone-sensitive prostate cancer recommended by NICE
August 15, 2024Research and Development Accord healthcare, Oncology, Reproductive health, hormone-sensitive, prostate cancer
Today, Accord Healthcare has announced that the National Institute for Health and Care excellence (NICE) have recommended the first oral …
FDA approves drug for primary biliary cholangitis
August 15, 2024Research and Development FDA Approval, FDA approva;, Hepatology, liver, primary biliary cholangitis
Accelerated approval has been granted for Gilead Science’s Livdelzi (seladelpar) to treat primary biliary cholangitis (PBC) by the US Food …
Kerato Ltd Partners with University of Montreal to develop novel treatment for corneal damage
August 14, 2024Research and Development Kerato, Opthalmology, University of Montreal, corenas
BSF the Main Market listed biotech company and owner of corneal tissue replacement company Kerato Ltd, is pleased to announce …
David Wheadon appointed to board of directors at Seaport Therapeutics
August 14, 2024Corporate, Seaport Therapeutics, appointment
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
